These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported Terminated 2008-006765-82 Preventive therapy for multidrug-resistant tuberculosis: a multicentre clincal trial. 2014-01-29 due-trials
Reported results 2009-016697-32 PRotease-Inhibitors MOnotherapy Strategies as maintenance therapy in persons with fully suppressed HIV replication: results from an open-label randomized comparative trial (PRIMO Trial) 2014-10-27 due-trials
Completed, but no date Terminated 2009-016705-42 Pilot study on efficacy of a simplification strategy from DRV/r 600/100 mg BID to DRV/r 800/100mg QD + OBT in HIV-positive patients HAART-experienced with virological response. bad-data
Ongoing 2010-023245-30 Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis not-yet-due
Ongoing 2011-004038-33 Non-inferiority,randomized clinical trial to evaluate the efficacy and the safety of the use of fixed-dose combination efavirenz/tenofovir/emtricitabine (Atripla) administered in alternate days versu... not-yet-due
Completed, but no date Terminated 2011-004693-29 Pegylated interferon alfa-2a USE FOR CONTROLLING virological rebound after suspension of antiretroviral treatment IN PATIENTS WITH CHRONIC HIV INFECTION USO DELL’INTERFERONE ALFA-2A PEGHILATO PER ... bad-data
Ongoing 2011-005270-35 HIV-infected pregnant women treated with HAART: registry of pharmacokinetic parameters of new and commonly used antiretrovirals DONNE CON INFEZIONE DA HIV TRATTATE CON HAART: REGISTRO DEI PARAMETR... not-yet-due
Completed, but no date 2014-003874-17 Antiretroviral Pre-exposure prophylaxis for natural conception (PrEP-C) in serodiscordant female partners of HIV-infected men in sustained virologic suppression Profilassi antiretrovirale pre-espo... bad-data
Ongoing 2016-002006-39 Study on Efficacy and safety of an early proactive Switch To ElvitegraviR/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in patients with a primary HIV-1 infection Study on Efficacy and... not-yet-due
Ongoing 2018-003880-79 Efficacy and safety of the switch from Efavirenz / emtricitabine / tenofovir difumarate taken once daily or alternate days to Bictegravir / emtricitabine / tenofovir alafenamide in HIV + virologically... not-yet-due
Ongoing 2019-002514-40 Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with pulmonary tuberculosis: a new therapy for tuberculosis dire... not-yet-due
Ongoing 2019-003614-14 Feasibility, efficacy and safety of rapid (within 7 days from HIV diagnosis) antiretroviral initiation strategy based on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-infected naïve... not-yet-due
Ongoing 2020-001390-76 A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients... not-yet-due
Completed, but no date Terminated 2020-001528-32 Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals Studio randomizzato adattivo per la terapia della malattia da Corona virus 2019 a casa con antivirali... bad-data
Ongoing 2021-000243-50 Understanding the Impact of HIV-DNA resistance mutations detected by NGS in Simplification strategies to 2-Drug Regimens for patients virologically suppressed with previous failures and/or previous re... not-yet-due
Ongoing 2021-004188-28 A Phase III Randomized, Open-label, Multicenter Study to Determine the Safety and Efficacy of different MONoclonal Antibodies (MoAbs) to SARS-CoV-2 for the Early Treatment of COVID-19 in Non-hospitali... not-yet-due
Ongoing 2021-006495-16 Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders Immunogenicità e sicurezza di Sotrovimab (Vir 7831) IV come profilassi primari... not-yet-due
Ongoing 2022-000905-29 Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies Cinetica tempoRale de... not-yet-due
Ongoing 2022-001819-12 Cysteamine in association with standard therapy for the treatment of hospitalized patients with COVID-19 pneumonia: phase 2 study on safety of a new antiviral and direct therapy on the host Cisteam... not-yet-due